Key result
CRT reverses dyssynchronous heart failure phospho-proteomic changes in dog models by modulating CK2 targets.
Why the study?
Does cardiac resynchronization therapy alter the phospho-proteome in dog models of dyssynchronous heart failure?
Does cardiac resynchronization therapy alter the phospho-proteome in dog models of dyssynchronous heart failure?
CRT reverses specific hyper-phosphorylation patterns seen in dyssynchronous heart failure, particularly involving CK2 signaling, suggesting a potential therapeutic target to complement CRT.
Cardiac dyssynchrony arises from conduction abnormalities during heart failure and worsens morbidity and mortality. Cardiac resynchronization therapy (CRT) re‐coordinates contraction using bi‐ventricular pacing, but the cellular and molecular mechanisms involved remain largely unknown. The aim is to determine how dyssynchronous heart failure (HF dys ) alters the phospho‐proteome and how CRT interacts with this unique phospho‐proteome by analyzing Ser/Thr and Tyr phosphorylation. Phospho‐enriched myocardium from dog models of Control, HF dys , and CRT is analyzed via MS. There were 209 regulated phospho‐sites among 1761 identified sites. Compared to Con and CRT, HF dys is hyper‐phosphorylated and tyrosine phosphorylation is more likely to be involved in signaling that increased with HF dys and was exacerbated by CRT. For each regulated site, the most‐likely targeting‐kinase is predicted, and CK2 is highly specific for sites that are “fixed” by CRT, suggesting activation of CK2 signaling occurs in HF dys that is reversed by CRT, which is supported by western blot analysis. These data elucidate signaling networks and kinases that may be involved and deserve further study. Importantly, a possible role for CK2 modulation in CRT has been identified. This may be harnessed in the future therapeutically to compliment CRT, improving its clinical effects.
No takes yet. Share an insight, caveat, or question.
Stachowski et al. (2018) studied Cardiac dyssynchrony and heart failure. Cardiac resynchronization therapy (CRT) vs. Control and dyssynchronous heart failure was evaluated on Regulated phospho-sites (Ser/Thr and Tyr phosphorylation). Cardiac resynchronization therapy in dog models reversed specific phospho-proteomic changes induced by dyssynchronous heart failure, particularly modulating sites targeted by the kinase CK2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: